Horizon - Model HZN-825 -Diffuse Cutaneous Systemic Sclerosis

A molecule that blocks lysophosphatidic acid receptor 1 (LPAR₁). We are conducting a Phase 2b pivotal trial in diffuse cutaneous systemic sclerosis and a Phase 2b pivotal trial in idiopathic pulmonary fibrosis.